<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413320</url>
  </required_header>
  <id_info>
    <org_study_id>2015-IIT-Neoadjuvant-BRST-TNBC</org_study_id>
    <nct_id>NCT02413320</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer</brief_title>
  <acronym>NeoSTOP</acronym>
  <official_title>Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Priyanka Sharma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of
      breast cancer cells in women with Stage I, II, or III triple negative breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sporadic and germline BRCA mutation associated triple-negative breast cancer share several
      pathological and molecular similarities which have led to the exploration of DNA damaging
      agents like platinum compounds in patients with triple-negative breast cancer. Recent studies
      demonstrate that addition of neoadjuvant carboplatin to
      doxorubicin/cyclophosphamide/taxane-based chemotherapy improves pathological complete
      response in patients with stage I-III triple-negative breast cancer but also increase
      toxicity.

      A recent study reported encouraging pathological complete response rates with a
      non-anthracycline carboplatin plus docetaxel neoadjuvant chemotherapy regimen in a cohort of
      49 triple negative breast cancer patients. This chemotherapy regimen of carboplatin plus
      docetaxel yielded an overall pathological complete response rate of 65% in unselected
      triple-negative breast cancer with pathological complete response rates of 61% in sporadic
      and 77% in germline BRCA-associated triple-negative breast cancer. The chemotherapy regimen
      of carboplatin/docetaxel is well tolerated and should be studied further and compared with
      regimens that add carboplatin to the standard anthracycline/taxane containing regimens.

      This is the basis for the proposed randomized neoadjuvant phase II study to further estimate
      and compare pathological complete response rates of carboplatin plus docetaxel x 6 cycles to
      carboplatin plus paclitaxel x 4 cycles followed by doxorubicin plus cyclophosphamide x 4
      cycles in stage I-III triple negative-breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rates</measure>
    <time_frame>20 weeks</time_frame>
    <description>To evaluate the pathological complete response rates with neoadjuvant chemotherapy regimens of carboplatin plus paclitaxel x 4 cycles followed by doxorubicin plus cyclophosphamide X 4 cycles and carboplatin plus docetaxel X 6 cycles in subjects with stage I-III triple-negative breast cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease rates</measure>
    <time_frame>20 weeks</time_frame>
    <description>To evaluate minimal residual disease rates with two neoadjuvant chemotherapy regimens in subjects with stage I-III triple-negative breast cancer.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pathological complete response and minimal residual disease rates in germline BRCA associated and BRCA wild type triple-negative breast cancer</measure>
    <time_frame>20 weeks</time_frame>
    <description>Compare pathological complete response and minimal residual disease rates in subjects with germline BRCA associated and BRCA wild type triple-negative breast cancer with the two neoadjuvant chemotherapy regimens.</description>
  </other_outcome>
  <other_outcome>
    <measure>Difference in cost associated with two chemotherapy regimens to treat triple-negative breast cancer</measure>
    <time_frame>20 weeks</time_frame>
    <description>Assessment of cost associated with the delivery of the two chemotherapy regimens.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Triple-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (600mg/m2) given IV every 14 days X 4 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin + Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin (AUC 6) given IV and Docetaxel (75mg/m2) given IV every 21 days x 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide</arm_group_label>
    <other_name>taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide</arm_group_label>
    <arm_group_label>Carboplatin + Docetaxel</arm_group_label>
    <other_name>paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide</arm_group_label>
    <other_name>adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide</arm_group_label>
    <other_name>cytoxin, procytox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Carboplatin + Docetaxel</arm_group_label>
    <other_name>taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed stage I (T&gt;1cm), II or III triple negative breast cancer
             who have not had definitive breast surgery or received systemic chemotherapy

          -  The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor
             and progesterone receptor staining present in ≤ 10% of invasive cancer cells by
             Immunohistochemistry.

          -  HER- 2 negativity will be based on the current ASCO-CAP guidelines for HER testing

          -  No prior chemotherapy, endocrine therapy or radiation therapy with therapeutic intent
             for this cancer

          -  Female subjects age 18 - 70 years

          -  ECOG Performance Status of 0-1

          -  Adequate organ and marrow function as defined below:

               -  Leukocytes ≥ 3,000/uL

               -  Absolute neutrophil count ≥ 1500/uL

               -  Platelets ≥ 100,000/uL

               -  Total bilirubin ≤ 1.5mg/dL

               -  AST(SGOT)/ALT(SPGT) ≤ 2 x institutional upper limit of normal

               -  Creatinine ≤ 1.5mg/dl and/or Creatinine Clearance ≥ 60mL/min

               -  Serum albumin ≥ 3.0 g/dL

          -  Women of child-bearing potential must agree to use adequate contraception

          -  Pretreatment lab values must be performed within 14 days of treatment initiation, and
             other baseline studies performed within 30 days prior to registration

          -  Subjects should have LVEF ≥ 50% by echocardiogram or MUGA scan performed within 4
             weeks prior to treatment initiation

          -  Subjects should have breast and axillary imaging with breast MRI or breast and
             axillary ultrasound within 4 weeks prior to treatment initiation

          -  Subjects with clinically/radiologically abnormal axillary lymph nodes should have
             pathological confirmation of disease with image guided biopsy/fine needle aspiration.

          -  Subjects must be already enrolled in P.R.O.G.E.C.T observational registry

          -  Staging to rule out metastatic disease is recommended for subjects with clinical stage
             III disease

          -  Subjects with bilateral disease are eligible if they meet other eligibility criteria.

          -  Neuropathy: No baseline neuropathy grade &gt; 2

        Exclusion Criteria:

          -  Current or anticipated use of other investigational agents

          -  Subject has received chemotherapy, radiotherapy or surgery for the treatment of breast
             cancer

          -  Subject with metastatic disease

          -  History of allergic reactions to compounds of similar chemical or biologic composition
             to carboplatin, docetaxel, doxorubicin, cyclophosphamide, paclitaxel, or other agents
             used in the study

          -  Subjects with inflammatory breast cancer

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Subject is pregnant or nursing

          -  Subjects with concomitant or previous malignancies within the last 5 years. Exceptions
             include: adequately treated basal or squamous cell carcinoma of the skin, carcinoma in
             situ of the cervix, and ductal carcinoma in situ (DCIS).

          -  Ejection Fraction &lt;50% on ECHO or MUGA

          -  Cardiac function: Subjects with congestive heart failure, myocardial infarction,
             unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia
             attack within the past 12 months, uncontrolled hypertension (Systolic BP&gt;160 or
             Diastolic BP&gt;90), uncontrolled or symptomatic arrhythmia, or grade ≥ 2 peripheral
             vascular disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priyanka Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kerry Hepler, RN</last_name>
    <email>ctnursenav@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - CRC</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Hepler, RN</last_name>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hays Medical Center</name>
      <address>
        <city>Hays</city>
        <state>Kansas</state>
        <zip>67601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josette Klaus, RN</last_name>
      <phone>785-623-5761</phone>
      <email>josette.klaus@haysmed.com</email>
    </contact>
    <contact_backup>
      <last_name>Shawn Mulkey, RN</last_name>
      <phone>785-623-5774</phone>
      <email>shawn.mulkey@hays.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - Overland Park</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Nurse Navigator</last_name>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salina Regional Health Center</name>
      <address>
        <city>Salina</city>
        <state>Kansas</state>
        <zip>67401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Leepers, RN</last_name>
      <phone>785-452-7038</phone>
      <email>mleepers@srhc.com</email>
    </contact>
    <contact_backup>
      <last_name>Lynn Marshall, RN</last_name>
      <phone>785-452-7335</phone>
      <email>lmarshal@srhc.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - Westwood</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Hepler, RN</last_name>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Truman Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Sharp, RN</last_name>
      <phone>816-404-4045</phone>
      <email>Denise.Sharp@tmcmed.org</email>
    </contact>
    <contact_backup>
      <last_name>Nikki Malomo</last_name>
      <phone>816-404-4093</phone>
      <email>nikki.malomo@tmc.med.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - South</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Nurse Navigator, RN</last_name>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - North</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Hepler, RN</last_name>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - Lee's Summit</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Hepler</last_name>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Priyanka Sharma</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>TNBC, breast cancer, neoadjuvant, carboplatin, docetaxel, paclitaxel, doxorubicin, cyclophosphamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

